

DOCKET NO.: DM-6964C (BMS-2595)  
 Application No.: 10/786,992  
 Office Action Dated: April 1, 2005


PATENT

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-9. Canceled.

10. (Currently amended) A compound of formula (VI):



wherein:

r is an integer from 0 to 4;

R<sup>1</sup> is independently selected at each occurrence from the group consisting of:  
 H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>12</sub> cycloalkylalkyl, -NR<sup>1c</sup>R<sup>1d</sup>, -OR<sup>1e</sup>, and -SR<sup>1e</sup>;

R<sup>1c</sup> and R<sup>1d</sup> are independently selected at each occurrence from the group consisting of:  
 H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl and C<sub>4</sub>-C<sub>12</sub> cycloalkylalkyl;

alternatively, R<sup>1c</sup> and R<sup>1d</sup> are taken together to form a heterocyclic ring selected from the group consisting of:

piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine and thiomorpholine, each heterocyclic ring optionally substituted with 1-3 C<sub>1</sub>-C<sub>4</sub> alkyl groups;

R<sup>1e</sup> is independently selected at each occurrence from the group consisting of:  
 H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, and C<sub>4</sub>-C<sub>6</sub> cycloalkylalkyl;

R<sup>2</sup> is selected from the group consisting of:  
 H, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>10</sub> cycloalkylalkyl, C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> alkyl substituted with 0-5 R<sup>2a</sup>;

R<sup>2a</sup> is independently selected at each occurrence from the group consisting of:

PATENT

DOCKET NO.: DM-6964C (BMS-2595)  
 Application No.: 10/786,992  
 Office Action Dated: April 1, 2005

H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>12</sub> cycloalkylalkyl, halo, CN, C<sub>1</sub>-C<sub>4</sub> haloalkyl, -OR<sup>2e</sup>, and -SR<sup>2e</sup>; and  
 R<sup>2e</sup> is independently selected at each occurrence from the group consisting of:

H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, and C<sub>4</sub>-C<sub>6</sub> cycloalkylalkyl;

with the following provisos:

- (1) when R<sup>2</sup> is H, methyl or ethyl, r is an integer from 1 to 4; and
- (2) when R<sup>2</sup> is unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl, R<sup>1</sup> is not OH.

11. Canceled.

12. Canceled

13. (Currently added) A compound according to claim 10 that is selected from the group consisting of:

- 4-(4-methoxy-2-methyl)phenyl-5-methylisoxazole; and
- 4-(2,5-dimethyl-4-methoxy)phenyl-5-methylisoxazole.

14. (Currently added) A compound according to claim 13 that is 4-(2,5-dimethyl-4-methoxy)phenyl-5-methylisoxazole.